The company have been pursuing non-dilutive funding since 2015. As such, CR is not an option unless absolutely necessary (for survival, not for trials).
Yesterday's Business Review Announcement and the Investor Update published in June are both well-structured presentations for drawing the attention from potential investors/partners and increasing their interest in the superior Deoxymab assets as well as keeping the existing shareholders posted. Also, these two plain language documents can be deemed as executive summaries which its target audience are those prospective partners' decision makers.
JMT, DYOR
Ann: PAB Business Review - 30 June 2017, page-7
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.172M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $16.52K | 5.509M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 29 | 58406173 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 10870910 | 15 |
View Market Depth
| Last trade - 11.22am 07/11/2024 (20 minute delay) ? |
| PAB (ASX) Chart |